Navigation Links
Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP
Date:7/24/2008

SCHAUMBURG, Ill., July 24 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched ceftazidime for injection, USP, a semisynthetic broad-spectrum, beta-lactam antibiotic. Sagent will offer ceftazidime in 1 and 2g single dose vials and 6g pharmacy bulk package vials. According to IMS data, 2007 sales of injectable amiodarone in the United States were approximately $45.7 million.

"Sagent is proud to be providing tools to the healthcare community that have the potential to help reduce medical errors," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "We are excited to make important products like ceftazidime available with exciting innovations, such as easy-to-read dosage strengths and precise lettering on vial labels that are intended to promote patient safety."

Sagent's introduction of ceftazidime to the U.S. market is the seventh product launched from Sagent's pipeline of more than 200 products this year.

About Ceftazidime

Ceftazidime for Injection, USP is a semisynthetic broad-spectrum, beta-lactam antibiotic used to treat bacterial infections, including infections of the lower respiratory tract; skin and skin-structure; urinary tract; bone and joint; and central nervous system. Ceftazidime is also indicated for bacterial septicemia, gynecologic infections, and intra-abdominal infections. Sagent's ceftazidime is the generic equivalent of GlaxoSmithKline's FORTAZ(R).

The most common adverse effects include diarrhea, headache, stomach pain, nausea, vomiting, and numbness or tingling of the skin. Less common adverse effects include abnormal muscle movements, severe stomach cramps, severe nausea or vomiting, bloody stools, severe diarrhea, decreased urination, vaginal irritation or discharge, fever, white patches in the mouth, hoarseness, jaundice, injection site reactions, vein inflammation and red, swollen or blistered skin, seizures.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit http://www.SagentPharma.com.


'/>"/>
SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sagent Pharmaceuticals Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP
2. Sagent Pharmaceuticals Provides US$20,000 in Aid to Earthquake-Devastated Areas in Central China
3. Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
4. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
7. Anadys Pharmaceuticals to Report Second Quarter 2008 Financial Results
8. Sonus Pharmaceuticals Receives Favorable NASDAQ Decision
9. Jazz Pharmaceuticals Announces $26.0 Million Registered Direct Offering
10. Amylin Pharmaceuticals to Webcast Second Quarter Results
11. ViroPharma To Acquire Lev Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential ... use of DNA technology to an industry that is ...
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
Breaking Biology News(10 mins):